Eisai Presents Results of Post Hoc Analysis of Eribulin Mesylate (HALAVEN) at the European Society for Medical Oncology (ESMO) Congress 2022
Analysis Evaluates Efficacy of Eribulin in Metastatic HER2-low Breast Cancer Across Three Clinical StudiesTOKYO, Sept 12, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today results from a post hoc
Source: finanznachrichten.de